Merus N.V. Common Shares (MRUS) Dividend History

Company News

• Merus N.V. Announces Proposed Public Offering of Common Shares

  Merus N.V., an oncology company, announced a proposed underwritten public offering of its common shares. The company plans to use the net proceeds to advance the clinical development of its product candidates, for preclinical research and technology development, and for working capital and general corporate purposes.

  Benzinga
• Les données intermédiaires du pétosemtamab de Merus en association avec le pembrolizumab démontrent une réelle efficacité et une bonne durabilité dans le traitement de 1re ligne contre le CETC r/m PD-L1+

  Merus' petosemtamab in combination with pembrolizumab showed a 63% response rate and 79% overall survival rate at 12 months in the treatment of first-line PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma.

  GlobeNewswire Inc.
• Vorläufige Ergebnisse von Merus zu Petosemtamab mit Pembrolizumab zeigen robuste Wirksamkeit und Dauerhaftigkeit bei der Erstlinienbehandlung von PD-L1-positivem r/m HNSCC

  Merus reported positive interim data from a Phase 2 study of its bspecific antibody Petosemtamab in combination with Pembrolizumab for the first-line treatment of PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma. The data showed a 63% response rate and 79% 12-month overall survival rate.

  GlobeNewswire Inc.
• Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC

  Merus announced positive interim data from a phase 2 trial of its bispecific antibody petosemtamab in combination with pembrolizumab for the treatment of head and neck squamous cell carcinoma. The data showed a 63% response rate and 79% overall survival rate at 12 months.

  GlobeNewswire Inc.
• Merus annonce la publication d’un article sur le mécanisme d’action du pétosemtamab

  Merus, a clinical-stage oncology company, announces the publication of an article on the mechanism of action of its bispecific antibody candidate petosemtamab, which targets EGFR and LGR5. The article provides scientific rationale for the clinical data previously reported for petosemtamab in the treatment of recurrent/metastatic head and neck squamous cell carcinoma.

  GlobeNewswire Inc.